GATA3 and asthma: Notably, treatment with a DNA enzyme that cleaved GATA3 mRNA resulted in reduced airway eosinophilia and plasma levels of IL-5 in individuals with asthma (59, 60), highlighting the feasibility of targeting TFs in patients with eosinophil disorders.